{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:12:32Z","timestamp":1793686352703,"version":"4.5.1"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41569-026-01269-9","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T17:52:44Z","timestamp":1773165164000},"page":"741-756","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antiphospholipid antibodies and cardiovascular thrombosis"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0146-5611","authenticated-orcid":false,"given":"Sina","family":"Rashedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Leyva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1009-4800","authenticated-orcid":false,"given":"Saman A.","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Bukhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana B.","family":"Pfeferman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan W.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Ujueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Zarghami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassil","family":"Bacare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5660-5194","authenticated-orcid":false,"given":"Yogendra","family":"Kanthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4571-7721","authenticated-orcid":false,"given":"David","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0494-0767","authenticated-orcid":false,"given":"Manuel","family":"Monreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3806-3245","authenticated-orcid":false,"given":"Deborah M.","family":"Siegal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6532-8440","authenticated-orcid":false,"given":"Geoffrey D.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4126-1285","authenticated-orcid":false,"given":"John W.","family":"Eikelboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"O\u2019Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian T.","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany N.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Z.","family":"Goldhaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Uljon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1006-6420","authenticated-orcid":false,"given":"Saskia","family":"Middeldorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2999-4961","authenticated-orcid":false,"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2046-127X","authenticated-orcid":false,"given":"Harlan M.","family":"Krumholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0995-9771","authenticated-orcid":false,"given":"Jason S.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9523-9054","authenticated-orcid":false,"given":"Giuseppe","family":"Lippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2562-1156","authenticated-orcid":false,"given":"Mitchell S. V.","family":"Elkind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7871-6143","authenticated-orcid":false,"given":"Mary","family":"Cushman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8972-9388","authenticated-orcid":false,"given":"Karen H.","family":"Costenbader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1428-879X","authenticated-orcid":false,"given":"Behnood","family":"Bikdeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"1269_CR1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00281-022-00916-w","volume":"44","author":"JS Knight","year":"2022","unstructured":"Knight, J. S. & Kanthi, Y. Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. Semin. Immunopathol. 44, 347\u2013362 (2022).","journal-title":"Semin. Immunopathol."},{"key":"1269_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.thromres.2020.10.010","volume":"198","author":"Z Sayar","year":"2021","unstructured":"Sayar, Z., Moll, R., Isenberg, D. & Cohen, H. Thrombotic antiphospholipid syndrome: a practical guide to diagnosis and management. Thromb. Res. 198, 213\u2013221 (2021).","journal-title":"Thromb. Res."},{"key":"1269_CR3","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMra1705454","volume":"378","author":"D Garcia","year":"2018","unstructured":"Garcia, D. & Erkan, D. Diagnosis and management of the antiphospholipid syndrome. N. Engl. J. Med. 378, 2010\u20132021 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1269_CR4","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1177\/0961203309360810","volume":"19","author":"J Boles","year":"2010","unstructured":"Boles, J. & Mackman, N. Role of tissue factor in thrombosis in antiphospholipid antibody syndrome. Lupus 19, 370\u2013378 (2010).","journal-title":"Lupus"},{"key":"1269_CR5","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1002\/art.41460","volume":"72","author":"Y Zuo","year":"2020","unstructured":"Zuo, Y. et al. Anti-neutrophil extracellular trap antibodies and impaired neutrophil extracellular trap degradation in antiphospholipid syndrome. Arthritis Rheumatol. 72, 2130\u20132135 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1269_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11926-020-00936-1","volume":"22","author":"A Tambralli","year":"2020","unstructured":"Tambralli, A., Gockman, K. & Knight, J. S. NETs in APS: current knowledge and future perspectives. Curr. Rheumatol. Rep. 22, 67 (2020).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1269_CR7","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41569-024-01045-7","volume":"21","author":"F Porsch","year":"2024","unstructured":"Porsch, F. & Binder, C. J. Autoimmune diseases and atherosclerotic cardiovascular disease. Nat. Rev. Cardiol. 21, 780\u2013807 (2024).","journal-title":"Nat. Rev. Cardiol."},{"key":"1269_CR8","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/art.42624","volume":"75","author":"M Barbhaiya","year":"2023","unstructured":"Barbhaiya, M. et al. The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol. 75, 1687\u20131702 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1269_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis, S. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4, 295\u2013306 (2006).","journal-title":"J. Thromb. Haemost."},{"key":"1269_CR10","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/jama.295.9.1050","volume":"295","author":"W Lim","year":"2006","unstructured":"Lim, W., Crowther, M. A. & Eikelboom, J. W. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 295, 1050\u20131057 (2006).","journal-title":"JAMA"},{"key":"1269_CR11","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/0961203310395803","volume":"20","author":"G Ruiz-Irastorza","year":"2011","unstructured":"Ruiz-Irastorza, G. et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th international congress on antiphospholipid antibodies. Lupus 20, 206\u2013218 (2011).","journal-title":"Lupus"},{"key":"1269_CR12","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1002\/acr.22066","volume":"65","author":"L Andreoli","year":"2013","unstructured":"Andreoli, L. et al. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res. 65, 1869\u20131873 (2013).","journal-title":"Arthritis Care Res."},{"key":"1269_CR13","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","volume":"118","author":"AM Wendelboe","year":"2016","unstructured":"Wendelboe, A. M. & Raskob, G. E. Global burden of thrombosis: epidemiologic aspects. Circ. Res. 118, 1340\u20131347 (2016).","journal-title":"Circ. Res."},{"key":"1269_CR14","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","volume":"80","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan, M., Mensah, G. A., Turco, J. V., Fuster, V. & Roth, G. A. The global burden of cardiovascular diseases and risk. J. Am. Coll. Cardiol. 80, 2361\u20132371 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1269_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11239-023-02834-6","volume":"56","author":"B Grygiel-G\u00f3rniak","year":"2023","unstructured":"Grygiel-G\u00f3rniak, B. & Mazurkiewicz, \u0141. Positive antiphospholipid antibodies: observation or treatment? J. Thromb. Thrombolysis 56, 301\u2013314 (2023).","journal-title":"J. Thromb. Thrombolysis"},{"key":"1269_CR16","unstructured":"Bustamante, J. G., Goyal, A., Rout, P. & Singhal, M. Antiphospholipid Syndrome (StatPearls Publishing, 2024)."},{"key":"1269_CR17","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3389\/fneur.2018.01001","volume":"9","author":"T Fleetwood","year":"2018","unstructured":"Fleetwood, T., Cantello, R. & Comi, C. Antiphospholipid syndrome and the neurologist: from pathogenesis to therapy. Front. Neurol. 9, 1001 (2018).","journal-title":"Front. Neurol."},{"key":"1269_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.5152\/eurjrheum.2015.0085","volume":"3","author":"O \u00dcnl\u00fc","year":"2016","unstructured":"\u00dcnl\u00fc, O., Zuily, S. & Erkan, D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur. J. Rheumatol. 3, 75\u201384 (2016).","journal-title":"Eur. J. Rheumatol."},{"key":"1269_CR19","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s11239-015-1176-8","volume":"40","author":"NM Nascimento","year":"2015","unstructured":"Nascimento, N. M. et al. ABO blood group in primary antiphospholipid syndrome: influence in the site of thrombosis? J. Thromb. Thrombolysis 40, 374\u2013378 (2015).","journal-title":"J. Thromb. Thrombolysis"},{"key":"1269_CR20","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/rheumatology\/kead498","volume":"63","author":"H Jiang","year":"2024","unstructured":"Jiang, H. et al. Effect of smoking on thrombotic antiphospholipid syndrome: a 10-year prospective cohort study. Rheumatology 63, 1917\u20131922 (2024).","journal-title":"Rheumatology"},{"key":"1269_CR21","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.3390\/antiox10111790","volume":"10","author":"C Nocella","year":"2021","unstructured":"Nocella, C. et al. Oxidative stress in the pathogenesis of antiphospholipid syndrome: implications for the atherothrombotic process. Antioxidants 10, 1790 (2021).","journal-title":"Antioxidants"},{"key":"1269_CR22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41569-023-00937-4","volume":"21","author":"S Tsimikas","year":"2024","unstructured":"Tsimikas, S. & Witztum, J. L. Oxidized phospholipids in cardiovascular disease. Nat. Rev. Cardiol. 21, 170\u2013191 (2024).","journal-title":"Nat. Rev. Cardiol."},{"key":"1269_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00281-011-0285-5","volume":"34","author":"VW van Hinsbergh","year":"2012","unstructured":"van Hinsbergh, V. W. Endothelium \u2014 role in regulation of coagulation and inflammation. Semin. Immunopathol. 34, 93\u2013106 (2012).","journal-title":"Semin. Immunopathol."},{"key":"1269_CR24","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","volume":"18","author":"K Stark","year":"2021","unstructured":"Stark, K. & Massberg, S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat. Rev. Cardiol. 18, 666\u2013682 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"1269_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147958","volume":"11","author":"L Xia","year":"2016","unstructured":"Xia, L. et al. The effects of NF-\u03baB and c-Jun\/AP-1 on the expression of prothrombotic and proinflammatory molecules induced by anti-\u03b22GPI in mouse. PLoS ONE\u00a011, e0147958 (2016).","journal-title":"PLoS ONE"},{"key":"1269_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11926-009-0075-4","volume":"12","author":"KA Krone","year":"2010","unstructured":"Krone, K. A., Allen, K. L. & McCrae, K. R. Impaired fibrinolysis in the antiphospholipid syndrome. Curr. Rheumatol. Rep. 12, 53\u201357 (2010).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1269_CR27","doi-asserted-by":"publisher","first-page":"109804","DOI":"10.1016\/j.clim.2023.109804","volume":"256","author":"Z Ding","year":"2023","unstructured":"Ding, Z., Pan, H., Yang, Z., Yang, C. & Shi, H. Beyond the classics: the emerging value of anti-phosphatidylserine\/prothrombin antibodies in antiphospholipid syndrome. Clin. Immunol. 256, 109804 (2023).","journal-title":"Clin. Immunol."},{"key":"1269_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/rai2.12072","volume":"3","author":"J Li","year":"2023","unstructured":"Li, J., Zhu, X. & Feng, J. Role of \u03b22-glycoprotein I in the pathogenesis of the antiphospholipid syndrome. Rheumatol. Autoimmunity 3, 131\u2013139 (2023).","journal-title":"Rheumatol. Autoimmunity"},{"key":"1269_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/art.21549","volume":"54","author":"C L\u00f3pez-Pedrera","year":"2006","unstructured":"L\u00f3pez-Pedrera, C. et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB\/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1\/ERK pathway. Arthritis Rheum. 54, 301\u2013311 (2006).","journal-title":"Arthritis Rheum."},{"key":"1269_CR30","doi-asserted-by":"publisher","first-page":"13581","DOI":"10.3390\/ijms241713581","volume":"24","author":"T Reshetnyak","year":"2023","unstructured":"Reshetnyak, T. & Nurbaeva, K. The role of neutrophil extracellular traps (NETs) in the pathogenesis of systemic lupus erythematosus and antiphospholipid syndrome. Int. J. Mol. Sci. 24, 13581 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1269_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/antib6010004","volume":"6","author":"J Bravo-Barrera","year":"2017","unstructured":"Bravo-Barrera, J., Kourilovitch, M. & Galarza-Maldonado, C. Neutrophil extracellular traps, antiphospholipid antibodies and treatment. Antibodies 6, 4 (2017).","journal-title":"Antibodies"},{"key":"1269_CR32","doi-asserted-by":"crossref","unstructured":"Rand J. H., Wu X.-X. in Hughes Syndrome: Antiphospholipid Syndrome 2nd edn (ed. Khamashta, M. A.) 446\u2013456 (Springer, 2006).","DOI":"10.1007\/1-84628-009-5_36"},{"key":"1269_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069717","volume":"380","author":"JS Knight","year":"2023","unstructured":"Knight, J. S., Branch, D. W. & Ortel, T. L. Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ 380, e069717 (2023).","journal-title":"BMJ"},{"key":"1269_CR34","doi-asserted-by":"publisher","first-page":"SI4","DOI":"10.1093\/rheumatology\/kead603","volume":"63","author":"E Raschi","year":"2024","unstructured":"Raschi, E., Borghi, M. O., Tedesco, F. & Meroni, P. L. Antiphospholipid syndrome pathogenesis in 2023: an update of new mechanisms or just a reconsideration of the old ones? Rheumatology 63, SI4\u2013SI13 (2024).","journal-title":"Rheumatology"},{"key":"1269_CR35","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrrheum.2011.52","volume":"7","author":"PL Meroni","year":"2011","unstructured":"Meroni, P. L., Borghi, M. O., Raschi, E. & Tedesco, F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat. Rev. Rheumatol. 7, 330\u2013339 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1269_CR36","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3324\/haematol.2018.213991","volume":"105","author":"JC Gris","year":"2020","unstructured":"Gris, J. C. et al. Increased incidence of cancer in the follow-up of obstetric antiphospholipid syndrome within the NOH-APS cohort. Haematologica 105, 490\u2013497 (2020).","journal-title":"Haematologica"},{"key":"1269_CR37","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/jth.12537","volume":"12","author":"KM Devreese","year":"2014","unstructured":"Devreese, K. M. et al. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J. Thromb. Haemost. 12, 792\u2013795 (2014).","journal-title":"J. Thromb. Haemost."},{"key":"1269_CR38","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.3390\/jcm11082164","volume":"11","author":"A Vandevelde","year":"2022","unstructured":"Vandevelde, A. & Devreese, K. M. J. Laboratory diagnosis of antiphospholipid syndrome: insights and hindrances. J. Clin. Med. 11, 2164 (2022).","journal-title":"J. Clin. Med."},{"key":"1269_CR39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/978-1-0716-3175-1_19","volume":"2663","author":"EJ Favaloro","year":"2023","unstructured":"Favaloro, E. J., Mohammed, S., Vong, R. & Pasalic, L. Antiphospholipid antibody testing for anti-cardiolipin and anti-\u03b22 glycoprotein i antibodies using chemiluminescence-based panels. Methods Mol. Biol. 2663, 297\u2013314 (2023).","journal-title":"Methods Mol. Biol."},{"key":"1269_CR40","doi-asserted-by":"publisher","first-page":"102967","DOI":"10.1016\/j.rpth.2025.102967","volume":"9","author":"A Anunciaci\u00f3n-Llunell","year":"2025","unstructured":"Anunciaci\u00f3n-Llunell, A. et al. The absence of standardization in antiphospholipid antibody testing may favor the use of 99th percentile cutoffs in antiphospholipid syndrome classification. Res. Pract. Thromb. Haemost. 9, 102967 (2025).","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"1269_CR41","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/jth.14765","volume":"18","author":"MG Cattini","year":"2020","unstructured":"Cattini, M. G. et al. Tetra positive thrombotic antiphospholipid syndrome: major contribution of anti-phosphatidyl-serine\/prothrombin antibodies to lupus anticoagulant activity. J. Thromb. Haemost. 18, 1124\u20131132 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"1269_CR42","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1016\/j.jtha.2023.06.033","volume":"21","author":"E Pontara","year":"2023","unstructured":"Pontara, E. et al. Close link between antiphosphatidylserine\/prothrombin antibodies, lupus anticoagulant, and activated protein C resistance in tetra antiphospholipid antibody-positive subjects. J. Thromb. Haemost. 21, 3138\u20133144 (2023).","journal-title":"J. Thromb. Haemost."},{"key":"1269_CR43","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1111\/jth.15047","volume":"18","author":"KMJ Devreese","year":"2020","unstructured":"Devreese, K. M. J. et al. Guidance from the scientific and standardization committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J. Thromb. Haemost. 18, 2828\u20132839 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"1269_CR44","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41584-024-01110-y","volume":"20","author":"JS Knight","year":"2024","unstructured":"Knight, J. S. & Erkan, D. Rethinking antiphospholipid syndrome to guide future management and research. Nat. Rev. Rheumatol. 20, 377\u2013388 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1269_CR45","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1111\/jth.12264","volume":"11","author":"V Pengo","year":"2013","unstructured":"Pengo, V. et al. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J. Thromb. Haemost. 11, 1527\u20131531 (2013).","journal-title":"J. Thromb. Haemost."},{"key":"1269_CR46","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","volume":"81","author":"CD Khairani","year":"2023","unstructured":"Khairani, C. D. et al. Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials. J. Am. Coll. Cardiol. 81, 16\u201330 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1269_CR47","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/bjh.19635","volume":"205","author":"DJ Arachchillage","year":"2024","unstructured":"Arachchillage, D. J. et al. Guidelines on the investigation and management of antiphospholipid syndrome. Br. J. Haematol. 205, 855\u2013880 (2024).","journal-title":"Br. J. Haematol."},{"key":"1269_CR48","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jacc.2023.10.038","volume":"83","author":"A Bejjani","year":"2024","unstructured":"Bejjani, A. et al. When direct oral anticoagulants should not be standard treatment: JACC state-of-the-art review. J. Am. Coll. Cardiol. 83, 444\u2013465 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1269_CR49","doi-asserted-by":"publisher","first-page":"152741","DOI":"10.1016\/j.semarthrit.2025.152741","volume":"73","author":"AI Celia","year":"2025","unstructured":"Celia, A. I. et al. Direct oral anticoagulants versus vitamin K antagonists in antiphospholipid syndrome: a systematic review and meta-analysis. Semin. Arthritis Rheum. 73, 152741 (2025).","journal-title":"Semin. Arthritis Rheum."},{"key":"1269_CR50","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1136\/ard.2010.142042","volume":"70","author":"A Ruffatti","year":"2011","unstructured":"Ruffatti, A. et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann. Rheum. Dis. 70, 1083\u20131086 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"1269_CR51","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.thromres.2014.10.013","volume":"135","author":"V Pengo","year":"2015","unstructured":"Pengo, V. et al. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. Thromb. Res. 135, 46\u201349 (2015).","journal-title":"Thromb. Res."},{"key":"1269_CR52","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1182\/blood.2019003863","volume":"135","author":"S Chaturvedi","year":"2020","unstructured":"Chaturvedi, S. et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood 135, 239\u2013251 (2020).","journal-title":"Blood"},{"key":"1269_CR53","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1182\/blood-2014-09-551978","volume":"126","author":"TL Ortel","year":"2015","unstructured":"Ortel, T. L., Erkan, D. & Kitchens, C. S. How I treat catastrophic thrombotic syndromes. Blood 126, 1285\u20131293 (2015).","journal-title":"Blood"},{"key":"1269_CR54","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1093\/rheumatology\/key082","volume":"57","author":"I Rodr\u00edguez-Pint\u00f3","year":"2018","unstructured":"Rodr\u00edguez-Pint\u00f3, I., Espinosa, G., Erkan, D., Shoenfeld, Y. & Cervera, R. The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. Rheumatology 57, 1264\u20131270 (2018).","journal-title":"Rheumatology"},{"key":"1269_CR55","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/jth.13947","volume":"16","author":"E Pontara","year":"2018","unstructured":"Pontara, E. et al. Thrombocytopenia in high-risk patients with antiphospholipid syndrome. J. Thromb. Haemost. 16, 529\u2013532 (2018).","journal-title":"J. Thromb. Haemost."},{"key":"1269_CR56","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/jth.15082","volume":"19","author":"S Chaturvedi","year":"2021","unstructured":"Chaturvedi, S., Braunstein, E. M. & Brodsky, R. A. Antiphospholipid syndrome: complement activation, complement gene mutations, and therapeutic implications. J. Thromb. Haemost. 19, 607\u2013616 (2021).","journal-title":"J. Thromb. Haemost."},{"key":"1269_CR57","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","volume":"12","author":"H Berman","year":"2013","unstructured":"Berman, H. et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun. Rev. 12, 1085\u20131090 (2013).","journal-title":"Autoimmun. Rev."},{"key":"1269_CR58","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05671757 (2025)."},{"key":"1269_CR59","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.6530","volume":"6","author":"Y Zuo","year":"2023","unstructured":"Zuo, Y. et al. Prevalence of antiphospholipid antibodies and association with incident cardiovascular events. JAMA Netw. Open 6, e236530 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1269_CR60","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ijcard.2019.10.042","volume":"300","author":"C Selmi","year":"2020","unstructured":"Selmi, C. et al. Anti-phospholipid antibody prevalence and association with subclinical atherosclerosis and atherothrombosis in the general population. Int. J. Cardiol. 300, 209\u2013213 (2020).","journal-title":"Int. J. Cardiol."},{"key":"1269_CR61","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1055\/s-0038-1648840","volume":"72","author":"P Vila","year":"1994","unstructured":"Vila, P., Hern\u00e1ndez, M. C., L\u00f3pez-Fern\u00e1ndez, M. F. & Batlle, J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb. Haemost. 72, 209\u2013213 (1994).","journal-title":"Thromb. Haemost."},{"key":"1269_CR62","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11926-021-01038-2","volume":"23","author":"JY Dabit","year":"2022","unstructured":"Dabit, J. Y., Valenzuela-Almada, M. O., Vallejo-Ramos, S. & Duarte-Garc\u00eda, A. Epidemiology of antiphospholipid syndrome in the general population. Curr. Rheumatol. Rep. 23, 85 (2022).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1269_CR63","first-page":"557","volume":"69","author":"MN Manoussakis","year":"1987","unstructured":"Manoussakis, M. N. et al. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin. Exp. Immunol. 69, 557\u2013565 (1987).","journal-title":"Clin. Exp. Immunol."},{"key":"1269_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.932181","volume":"13","author":"S Truglia","year":"2022","unstructured":"Truglia, S. et al. Relationship between gender differences and clinical outcome in patients with the antiphospholipid syndrome. Front. Immunol. 13, 932181 (2022).","journal-title":"Front. Immunol."},{"key":"1269_CR65","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.autrev.2014.10.019","volume":"14","author":"L Arnaud","year":"2015","unstructured":"Arnaud, L. et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun. Rev. Mar. 14, 192\u2013200 (2015).","journal-title":"Autoimmun. Rev. Mar."},{"key":"1269_CR66","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1002\/art.22663","volume":"56","author":"D Erkan","year":"2007","unstructured":"Erkan, D. et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 56, 2382\u20132391 (2007).","journal-title":"Arthritis Rheum."},{"key":"1269_CR67","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/rheumatology\/ket313","volume":"53","author":"MJ Cuadrado","year":"2014","unstructured":"Cuadrado, M. J. et al. Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology 53, 275\u2013284 (2014).","journal-title":"Rheumatology"},{"key":"1269_CR68","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/j.jacc.2017.02.058","volume":"69","author":"MT Corban","year":"2017","unstructured":"Corban, M. T. et al. Antiphospholipid syndrome: role of vascular endothelial cells and implications for risk stratification and targeted therapeutics. J. Am. Coll. Cardiol. 69, 2317\u20132330 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1269_CR69","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1136\/annrheumdis-2013-203622","volume":"73","author":"D Erkan","year":"2014","unstructured":"Erkan, D. et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann. Rheum. Dis. 73, 1176\u20131180 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"1269_CR70","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1016\/j.jtha.2025.08.027","volume":"23","author":"D Marova","year":"2025","unstructured":"Marova, D. et al. Simvastatin competitively inhibits cellular signaling of lipid-binding antiphospholipid antibodies. J. Thromb. Haemost. 23, 3883\u20133894 (2025).","journal-title":"J. Thromb. Haemost."},{"key":"1269_CR71","doi-asserted-by":"publisher","DOI":"10.1055\/a-2664-7887","author":"B Bikdeli","year":"2025","unstructured":"Bikdeli, B. et al. Comparative effectiveness research using randomized trials and observational studies: validity and feasibility considerations. Thromb. Haemost. https:\/\/doi.org\/10.1055\/a-2664-7887 (2025).","journal-title":"Thromb. Haemost."},{"key":"1269_CR72","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12959-024-00610-x","volume":"22","author":"D Gjermeni","year":"2024","unstructured":"Gjermeni, D. et al. D-dimer and fibrinogen indicate ischemic risk in patients with atrial fibrillation after percutaneous coronary intervention. Thromb. J. 22, 42 (2024).","journal-title":"Thromb. J."},{"key":"1269_CR73","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1016\/j.jtha.2024.05.038","volume":"22","author":"M Hanarz","year":"2024","unstructured":"Hanarz, M., Z\u0105bczyk, M., Natorska, J., Baran, M. & Undas, A. Positive antiphospholipid antibodies increase the risk of ischemic stroke in patients with atrial fibrillation. J. Thromb. Haemost. 22, 2797\u20132809 (2024).","journal-title":"J. Thromb. Haemost."},{"key":"1269_CR74","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1182\/blood.V86.10.3685.bloodjournal86103685","volume":"86","author":"JS Ginsberg","year":"1995","unstructured":"Ginsberg, J. S. et al. Antiphospholipid antibodies and venous thromboembolism. Blood 86, 3685\u20133691 (1995).","journal-title":"Blood"},{"key":"1269_CR75","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1055\/s-0038-1650380","volume":"75","author":"P Prandoni","year":"1996","unstructured":"Prandoni, P., Simioni, P. & Girolami, A. Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation. Thromb. Haemost. 75, 859 (1996).","journal-title":"Thromb. Haemost."},{"key":"1269_CR76","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1055\/s-0038-1655939","volume":"77","author":"A Rance","year":"1997","unstructured":"Rance, A., Emmerich, J. & Fiessinger, J. N. Anticardiolipin antibodies and recurrent thromboembolism. Thromb. Haemost. 77, 221\u2013222 (1997).","journal-title":"Thromb. Haemost."},{"key":"1269_CR77","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S0002-9343(98)00060-6","volume":"104","author":"S Schulman","year":"1998","unstructured":"Schulman, S., Svenungsson, E. & Granqvist, S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am. J. Med. 104, 332\u2013338 (1998).","journal-title":"Am. J. Med."},{"key":"1269_CR78","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1159\/000081507","volume":"33","author":"I Bank","year":"2003","unstructured":"Bank, I. et al. Acquired and inherited thrombophilic factors and the risk for residual venous thrombosis. Pathophysiol. Haemost. Thromb. 33, 192\u2013196 (2003).","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"1269_CR79","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1365-2141.2006.05960.x","volume":"133","author":"K W\u00e5hlander","year":"2006","unstructured":"W\u00e5hlander, K. et al. Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism. Br. J. Haematol. 133, 68\u201377 (2006).","journal-title":"Br. J. Haematol."},{"key":"1269_CR80","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1177\/1358863X16668588","volume":"21","author":"SZ Goldhaber","year":"2016","unstructured":"Goldhaber, S. Z. et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: findings from RE-COVER\u00ae, RE-COVER\u2122 II, and RE-MEDY\u2122. Vasc. Med. 21, 506\u2013514 (2016).","journal-title":"Vasc. Med."},{"key":"1269_CR81","doi-asserted-by":"publisher","first-page":"100050","DOI":"10.1016\/j.rpth.2023.100050","volume":"7","author":"T Justinussen","year":"2023","unstructured":"Justinussen, T., Gram, J. B. & Bor, M. V. Antiphospholipid antibodies in pulmonary embolism treated with direct oral anticoagulants: prevalence data from unselected consecutive patients. Res. Pract. Thromb. Haemost. 7, 100050 (2023).","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"1269_CR82","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJM199903253401201","volume":"340","author":"C Kearon","year":"1999","unstructured":"Kearon, C. et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N. Engl. J. Med. 340, 901\u2013907 (1999).","journal-title":"N. Engl. J. Med."},{"key":"1269_CR83","doi-asserted-by":"publisher","first-page":"4432","DOI":"10.1182\/blood-2008-06-163279","volume":"112","author":"C Kearon","year":"2008","unstructured":"Kearon, C. et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood 112, 4432\u20134436 (2008).","journal-title":"Blood"},{"key":"1269_CR84","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1503\/cmaj.080493","volume":"179","author":"MA Rodger","year":"2008","unstructured":"Rodger, M. A. et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 179, 417\u2013426 (2008).","journal-title":"CMAJ"},{"key":"1269_CR85","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1160\/TH08-07-0477","volume":"101","author":"MR Taliani","year":"2009","unstructured":"Taliani, M. R. et al. Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities. Thromb. Haemost. 101, 596\u2013598 (2009).","journal-title":"Thromb. Haemost."},{"key":"1269_CR86","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1182\/blood-2017-09-805689","volume":"131","author":"C Kearon","year":"2018","unstructured":"Kearon, C. et al. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood 131, 2151\u20132160 (2018).","journal-title":"Blood"},{"key":"1269_CR87","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/jth.14720","volume":"18","author":"S Miranda","year":"2020","unstructured":"Miranda, S. et al. Prevalence of confirmed antiphospholipid syndrome in 18-50 years unselected patients with first unprovoked venous thromboembolism. J. Thromb. Haemost. 18, 926\u2013930 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"1269_CR88","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1046\/j.1538-7836.2004.00698.x","volume":"2","author":"C Kearon","year":"2004","unstructured":"Kearon, C. et al. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J. Thromb. Haemost. 2, 743\u2013749 (2004).","journal-title":"J. Thromb. Haemost."},{"key":"1269_CR89","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.autrev.2010.10.006","volume":"10","author":"C Font","year":"2011","unstructured":"Font, C. et al. Solid cancer, antiphospholipid antibodies, and venous thromboembolism. Autoimmun. Rev. 10, 222\u2013227 (2011).","journal-title":"Autoimmun. Rev."},{"key":"1269_CR90","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/000331970105200206","volume":"52","author":"JM de Godoy","year":"2001","unstructured":"de Godoy, J. M., Batig\u00e1lia, F. & Braile, D. M. Superficial thrombophlebitis and anticardiolipin antibodies \u2014 report of association. Angiology 52, 127\u2013129 (2001).","journal-title":"Angiology"},{"key":"1269_CR91","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1001\/jama.2025.15222","volume":"334","author":"G Piazza","year":"2025","unstructured":"Piazza, G. et al. Superficial vein thrombosis: a review. JAMA 334, 2020\u20132030 (2025).","journal-title":"JAMA"},{"key":"1269_CR92","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.autrev.2018.04.009","volume":"17","author":"V Dufrost","year":"2018","unstructured":"Dufrost, V. et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun. Rev. 17, 1011\u20131021 (2018).","journal-title":"Autoimmun. Rev."},{"key":"1269_CR93","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1111\/jth.13379","volume":"14","author":"H Kelchtermans","year":"2016","unstructured":"Kelchtermans, H., Pelkmans, L., de Laat, B. & Devreese, K. M. IgG\/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis. J. Thromb. Haemost. 14, 1530\u20131548 (2016).","journal-title":"J. Thromb. Haemost."},{"key":"1269_CR94","doi-asserted-by":"publisher","first-page":"1701202","DOI":"10.1183\/13993003.01202-2017","volume":"51","author":"C Tromeur","year":"2018","unstructured":"Tromeur, C. et al. Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial. Eur. Respir. J. 51, 1701202 (2018).","journal-title":"Eur. Respir. J."},{"key":"1269_CR95","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s11926-007-0034-x","volume":"9","author":"T Avcin","year":"2007","unstructured":"Avcin, T. & Toplak, N. Antiphospholipid antibodies in response to infection. Curr. Rheumatol. Rep. 9, 212\u2013218 (2007).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1269_CR96","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/joim.13409","volume":"291","author":"E Svenungsson","year":"2022","unstructured":"Svenungsson, E. et al. Antiphospholipid antibodies in patients with myocardial infarction with and without obstructive coronary arteries. J. Intern. Med. Mar. 291, 327\u2013337 (2022).","journal-title":"J. Intern. Med. Mar."},{"key":"1269_CR97","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0002-9343(96)00226-4","volume":"101","author":"E Zuckerman","year":"1996","unstructured":"Zuckerman, E. et al. Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythmatosus patients: a controlled prospective study. Am. J. Med. 101, 381\u2013386 (1996).","journal-title":"Am. J. Med."},{"key":"1269_CR98","doi-asserted-by":"publisher","first-page":"277","DOI":"10.7326\/M18-2130","volume":"170","author":"G Grosso","year":"2019","unstructured":"Grosso, G. et al. Antiphospholipid antibodies in patients with myocardial infarction. Ann. Intern. Med. 170, 277\u2013280 (2019).","journal-title":"Ann. Intern. Med."},{"key":"1269_CR99","volume":"9","author":"S Rashedi","year":"2025","unstructured":"Rashedi, S., Pfeferman, M., Gregory, P. & Behnood, B. PB1736 Antiphospholipid antibodies and thromboembolis events in patients with ischemic heart disease. Res. Pract. Thrombosis Haemostasis. 9, 102930 (2025).","journal-title":"Res. Pract. Thrombosis Haemostasis."},{"key":"1269_CR100","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1161\/01.CIR.102.11.1258","volume":"102","author":"A Bili","year":"2000","unstructured":"Bili, A. et al. Anticardiolipin antibodies and recurrent coronary events: a prospective study of 1150 patients. thrombogenic factors, and recurrent coronary events investigators. Circulation 102, 1258\u20131263 (2000).","journal-title":"Circulation"},{"key":"1269_CR101","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3389\/fimmu.2019.00941","volume":"10","author":"T Kolitz","year":"2019","unstructured":"Kolitz, T., Shiber, S., Sharabi, I., Winder, A. & Zandman-Goddard, G. Cardiac manifestations of antiphospholipid syndrome with focus on its primary form. Front. Immunol. 10, 941 (2019).","journal-title":"Front. Immunol."},{"key":"1269_CR102","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/S0002-9149(00)00780-3","volume":"85","author":"N Guler","year":"2000","unstructured":"Guler, N., Bilge, M., Eryonucu, B., Erkoc, R. & Sayarlioglu, M. Relation between left ventricular and\/or left atrial thrombus and anticardiolipin antibodies in patients with acute myocardial infarction. Am. J. Cardiol. 85, 1391\u20131393 (2000).","journal-title":"Am. J. Cardiol."},{"key":"1269_CR103","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1477-9560-8-15","volume":"8","author":"E Okuyan","year":"2010","unstructured":"Okuyan, E., Okcun, B., Dinckal, M. H. & Mutlu, H. Risk factors for development of left ventricular thrombus after first acute anterior myocardial infarction-association with anticardiolipin antibodies. Thromb. J. 8, 15 (2010).","journal-title":"Thromb. J."},{"key":"1269_CR104","doi-asserted-by":"publisher","first-page":"A4361466","DOI":"10.1161\/circ.152.suppl_3.4361466","volume":"152","author":"N Watson","year":"2025","unstructured":"Watson, N. et al. Association between antiphospholipid antibody and ischemic stroke: a systematic review and meta-analysis. Circulation 152, A4361466 (2025).","journal-title":"Circulation"},{"key":"1269_CR105","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1161\/01.STR.23.2.189","volume":"23","author":"P Nencini","year":"1992","unstructured":"Nencini, P. et al. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 23, 189\u2013193 (1992).","journal-title":"Stroke"},{"key":"1269_CR106","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s004150170176","volume":"248","author":"O Heinzlef","year":"2001","unstructured":"Heinzlef, O., Abuaf, N., Cohen, A. & Amarenco, P. Recurrent stroke and vascular events in elderly patients with anticardiolipin antibodies: a prospective study. J. Neurol. 248, 373\u2013379 (2001).","journal-title":"J. Neurol."},{"key":"1269_CR107","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000048623","volume":"21","author":"D Tanne","year":"2002","unstructured":"Tanne, D. et al. Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study. Neuroepidemiology 21, 93\u201399 (2002).","journal-title":"Neuroepidemiology"},{"key":"1269_CR108","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1600-0404.2004.00241.x","volume":"109","author":"MP van Goor","year":"2004","unstructured":"van Goor, M. P., Alblas, C. L., Leebeek, F. W., Koudstaal, P. J. & Dippel, D. W. Do antiphospholipid antibodies increase the long-term risk of thrombotic complications in young patients with a recent TIA or ischemic stroke? Acta Neurol. Scand. 109, 410\u2013415 (2004).","journal-title":"Acta Neurol. Scand."},{"key":"1269_CR109","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1001\/jama.291.5.576","volume":"291","author":"SR Levine","year":"2004","unstructured":"Levine, S. R. et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 291, 576\u2013584 (2004).","journal-title":"JAMA"},{"key":"1269_CR110","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000441362","volume":"40","author":"CF Amory","year":"2015","unstructured":"Amory, C. F. et al. Antiphospholipid antibodies and recurrent thrombotic events: persistence and portfolio. Cerebrovasc. Dis. 40, 293\u2013300 (2015).","journal-title":"Cerebrovasc. Dis."},{"key":"1269_CR111","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s11239-018-1631-4","volume":"45","author":"MMI Schellekens","year":"2018","unstructured":"Schellekens, M. M. I. et al. Prothrombotic factors do not increase the risk of recurrent ischemic events after cryptogenic stroke at young age: the FUTURE study. J. Thromb. Thrombolysis 45, 504\u2013511 (2018).","journal-title":"J. Thromb. Thrombolysis"},{"key":"1269_CR112","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10067-018-4247-3","volume":"38","author":"N Ga\u0161per\u0161i\u010d","year":"2019","unstructured":"Ga\u0161per\u0161i\u010d, N. et al. Stroke and antiphospholipid syndrome-antiphospholipid antibodies are a risk factor for an ischemic cerebrovascular event. Clin. Rheumatol. 38, 379\u2013384 (2019).","journal-title":"Clin. Rheumatol."},{"key":"1269_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.665741","volume":"8","author":"L Naranjo","year":"2021","unstructured":"Naranjo, L. et al. Presence of extra-criteria antiphospholipid antibodies is an independent risk factor for ischemic stroke. Front. Cardiovasc. Med. 8, 665741 (2021).","journal-title":"Front. Cardiovasc. Med."},{"key":"1269_CR114","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1212\/WNL.48.1.91","volume":"48","author":"[No authors listed].","year":"1997","unstructured":"No authors listed]. Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. Neurology 48, 91\u201394 (1997).","journal-title":"Neurology"},{"key":"1269_CR115","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1161\/STROKEAHA.120.030431","volume":"51","author":"Y Kim","year":"2020","unstructured":"Kim, Y. & Kim, S. Y. Antiphospholipid antibody and recurrent ischemic stroke: a systematic review and meta-analysis. Stroke 51, 3728\u20133732 (2020).","journal-title":"Stroke"},{"key":"1269_CR116","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1161\/01.STR.0000031927.25510.D1","volume":"33","author":"RL Brey","year":"2002","unstructured":"Brey, R. L. et al. Antiphospholipid antibodies and stroke in young women. Stroke 33, 2396\u20132400 (2002).","journal-title":"Stroke"},{"key":"1269_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.872279","volume":"13","author":"L Chen","year":"2022","unstructured":"Chen, L., Zhang, P., Zhu, X., Zhang, M. & Deng, B. A cryptogenic stroke associated with infective endocarditis and antiphospholipid antibody syndrome: case report and literature review. Front. Neurol. 13, 872279 (2022).","journal-title":"Front. Neurol."},{"key":"1269_CR118","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/0741-5214(89)90054-2","volume":"9","author":"J Eldrup-Jorgensen","year":"1989","unstructured":"Eldrup-Jorgensen, J. et al. Hypercoagulable states and lower limb ischemia in young adults. J. Vasc. Surg. 9, 334\u2013341 (1989).","journal-title":"J. Vasc. Surg."},{"key":"1269_CR119","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1078-5884(05)80131-5","volume":"9","author":"LJ Fligelstone","year":"1995","unstructured":"Fligelstone, L. J. et al. Lupus anticoagulant in patients with peripheral vascular disease: a prospective study. Eur. J. Vasc. Endovasc. Surg. 9, 277\u2013283 (1995).","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"1269_CR120","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0741-5214(05)80035-7","volume":"23","author":"RJ Valentine","year":"1996","unstructured":"Valentine, R. J. et al. Lipoprotein (a), homocysteine, and hypercoagulable states in young men with premature peripheral atherosclerosis: a prospective, controlled analysis. J. Vasc. Surg. 23, 53\u201361 (1996).","journal-title":"J. Vasc. Surg."},{"key":"1269_CR121","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0002-9343(00)00600-8","volume":"109","author":"F Puisieux","year":"2000","unstructured":"Puisieux, F. et al. Association between anticardiolipin antibodies and mortality in patients with peripheral arterial disease. Am. J. Med. 109, 635\u2013641 (2000).","journal-title":"Am. J. Med."},{"key":"1269_CR122","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jvs.2018.09.062","volume":"70","author":"JI Torrealba","year":"2019","unstructured":"Torrealba, J. I., Osman, M. & Kelso, R. Hypercoagulability predicts worse outcomes in young patients undergoing lower extremity revascularization. J. Vasc. Surg. 70, 175\u2013180 (2019).","journal-title":"J. Vasc. Surg."},{"key":"1269_CR123","doi-asserted-by":"publisher","first-page":"A4361451","DOI":"10.1161\/circ.152.suppl_3.4361451","volume":"152","author":"N Watson","year":"2025","unstructured":"Watson, N. et al. Prevalence and outcomes of antiphospholipid antibodies in patients with peripheral artery disease. Circulation 152, A4361451 (2025).","journal-title":"Circulation"},{"key":"1269_CR124","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1160\/TH09-11-0772","volume":"104","author":"M Sartori","year":"2010","unstructured":"Sartori, M. et al. Thrombophilic risk factors and peripheral arterial disease severity. Thromb. Haemost. 104, 71\u201377 (2010).","journal-title":"Thromb. Haemost."},{"key":"1269_CR125","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0741-5214(96)70068-X","volume":"24","author":"RW Lee","year":"1996","unstructured":"Lee, R. W. et al. Prospective comparison of infrainguinal bypass grafting in patients with and without antiphospholipid antibodies. J. Vasc. Surg. 24, 524\u2013531 (1996).","journal-title":"J. Vasc. Surg."},{"key":"1269_CR126","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/0140-6736(90)91373-I","volume":"335","author":"MA Khamashta","year":"1990","unstructured":"Khamashta, M. A. et al. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 335, 1541\u20131544 (1990).","journal-title":"Lancet"},{"key":"1269_CR127","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/jth.14798","volume":"18","author":"CJ Lenz","year":"2020","unstructured":"Lenz, C. J., Mankad, R., Klarich, K., Kurmann, R. & McBane, R. D. Antiphospholipid syndrome and the relationship between laboratory assay positivity and prevalence of non-bacterial thrombotic endocarditis: a retrospective cohort study. J. Thromb. Haemost. 18, 1408\u20131414 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"1269_CR128","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s00059-013-4038-1","volume":"40","author":"A Aykan","year":"2015","unstructured":"Aykan, A. et al. Role of anticardiolipin antibodies in the pathogenesis of prosthetic valve thrombosis: an observational study. Herz 40, 528\u2013533 (2015).","journal-title":"Herz"},{"key":"1269_CR129","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1055\/s-0033-1357504","volume":"39","author":"MN Lauw","year":"2013","unstructured":"Lauw, M. N., Barco, S., Coutinho, J. M. & Middeldorp, S. Cerebral venous thrombosis and thrombophilia: a systematic review and meta-analysis. Semin. Thromb. Hemost. 39, 913\u2013927 (2013).","journal-title":"Semin. Thromb. Hemost."},{"key":"1269_CR130","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1161\/01.STR.28.12.2363","volume":"28","author":"JR Carhuapoma","year":"1997","unstructured":"Carhuapoma, J. R., Mitsias, P. & Levine, S. R. Cerebral venous thrombosis and anticardiolipin antibodies. Stroke 28, 2363\u20132369 (1997).","journal-title":"Stroke"},{"key":"1269_CR131","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1212\/01.wnl.0000297195.97325.a8","volume":"70","author":"EM Wysokinska","year":"2008","unstructured":"Wysokinska, E. M. et al. Thrombophilia differences in cerebral venous sinus and lower extremity deep venous thrombosis. Neurology 70, 627\u2013633 (2008).","journal-title":"Neurology"},{"key":"1269_CR132","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.2147\/OPTH.S34627","volume":"6","author":"CJ Glueck","year":"2012","unstructured":"Glueck, C. J., Hutchins, R. K., Jurantee, J., Khan, Z. & Wang, P. Thrombophilia and retinal vascular occlusion. Clin. Ophthalmol. 6, 1377\u20131384 (2012).","journal-title":"Clin. Ophthalmol."},{"key":"1269_CR133","doi-asserted-by":"publisher","first-page":"682","DOI":"10.7326\/0003-4819-112-9-682","volume":"112","author":"PE Love","year":"1990","unstructured":"Love, P. E. & Santoro, S. A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann. Intern. Med. 112, 682\u2013698 (1990).","journal-title":"Ann. Intern. Med."},{"key":"1269_CR134","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1177\/09612033241266989","volume":"33","author":"P Mittal","year":"2024","unstructured":"Mittal, P. et al. Comparison of clinical and serological features in thrombotic antiphospholipid syndrome patients, with and without associated systemic lupus erythematosus, followed for up to 42 years: a single centre retrospective study. Lupus 33, 1082\u20131088 (2024).","journal-title":"Lupus"},{"key":"1269_CR135","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40744-020-00273-w","volume":"8","author":"G El Hasbani","year":"2021","unstructured":"El Hasbani, G., Viola, M., Sciascia, S., Taher, A. T. & Uthman, I. Antiphospholipid antibodies in inflammatory and autoimmune rheumatic and musculoskeletal diseases beyond lupus: a systematic review of the available evidence. Rheumatol. Ther. 8, 81\u201394 (2021).","journal-title":"Rheumatol. Ther."},{"key":"1269_CR136","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.3389\/fimmu.2018.02457","volume":"9","author":"V Sobanski","year":"2018","unstructured":"Sobanski, V. et al. Prevalence and clinical associations of antiphospholipid antibodies in systemic sclerosis: new data from a french cross-sectional study, systematic review, and meta-analysis. Front. Immunol. 9, 2457 (2018).","journal-title":"Front. Immunol."},{"key":"1269_CR137","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1182\/bloodadvances.2020001557","volume":"4","author":"N Abdel-Wahab","year":"2020","unstructured":"Abdel-Wahab, N. et al. Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors. Blood Adv. 4, 1746\u20131755 (2020).","journal-title":"Blood Adv."},{"key":"1269_CR138","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/bjh.18239","volume":"198","author":"DJ Arachchillage","year":"2022","unstructured":"Arachchillage, D. J. et al. Thrombophilia testing: a British Society for Haematology guideline. Br. J. Haematol. 198, 443\u2013458 (2022).","journal-title":"Br. J. Haematol."},{"key":"1269_CR139","doi-asserted-by":"publisher","first-page":"7101","DOI":"10.1182\/bloodadvances.2023010177","volume":"7","author":"S Middeldorp","year":"2023","unstructured":"Middeldorp, S. et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 7, 7101\u20137138 (2023).","journal-title":"Blood Adv."},{"key":"1269_CR140","unstructured":"National Institute for Health and Care Excellence (NICE). Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. NICE guideline (NG158). nice.org.uk https:\/\/www.nice.org.uk\/guidance\/ng158\/chapter\/Recommendations#thrombophilia-testing (2023)."},{"key":"1269_CR141","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","volume":"61","author":"SK Kakkos","year":"2021","unstructured":"Kakkos, S. K. et al. Editor\u2019s choice - European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur. J. Vasc. Endovasc. Surg. 61, 9\u201382 (2021).","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"1269_CR142","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","volume":"52","author":"DO Kleindorfer","year":"2021","unstructured":"Kleindorfer, D. O. et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association. Stroke 52, e364\u2013e467 (2021).","journal-title":"Stroke"},{"key":"1269_CR143","doi-asserted-by":"publisher","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","volume":"149","author":"HL Gornik","year":"2024","unstructured":"Gornik, H. L. et al. 2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation 149, e1313\u2013e1410 (2024).","journal-title":"Circulation"},{"key":"1269_CR144","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","volume":"45","author":"L Mazzolai","year":"2024","unstructured":"Mazzolai, L. et al. ESC guidelines for the management of peripheral arterial and aortic diseases. Eur. Heart J. 45, 3538\u20133700 (2024).","journal-title":"Eur. Heart J."},{"key":"1269_CR145","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMra1700365","volume":"377","author":"JM Connors","year":"2017","unstructured":"Connors, J. M. Thrombophilia testing and venous thrombosis. N. Engl. J. Med. 377, 1177\u20131187 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1269_CR146","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41569-024-01003-3","volume":"21","author":"AH Talasaz","year":"2024","unstructured":"Talasaz, A. H. et al. Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease. Nat. Rev. Cardiol. 21, 574\u2013592 (2024).","journal-title":"Nat. Rev. Cardiol."},{"key":"1269_CR147","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/CMR.0000000000000335","volume":"27","author":"A Gupta","year":"2017","unstructured":"Gupta, A., Shah, U., Khine, H., Vandergriff, T. & Froehlich, T. Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy. Melanoma Res. 27, 171\u2013173 (2017).","journal-title":"Melanoma Res."},{"key":"1269_CR148","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1111\/1346-8138.17063","volume":"51","author":"M Hayashi","year":"2024","unstructured":"Hayashi, M. et al. Cutaneous arteritis combined with antiphospholipid syndrome associated with the use of immune checkpoint inhibitors in a patient with a metastatic lung adenocarcinoma. J. Dermatol. 51, e166\u2013e167 (2024).","journal-title":"J. Dermatol."},{"key":"1269_CR149","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954764","volume":"13","author":"DJM van Mourik","year":"2022","unstructured":"van Mourik, D. J. M., Salet, D. M., Middeldorp, S., Nieuwdorp, M. & van Mens, T. E. The role of the intestinal microbiome in antiphospholipid syndrome. Front. Immunol. 13, 954764 (2022).","journal-title":"Front. Immunol."},{"key":"1269_CR150","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11926-019-0869-y","volume":"21","author":"L Ortiz-Fern\u00e1ndez","year":"2019","unstructured":"Ortiz-Fern\u00e1ndez, L. & Sawalha, A. H. Genetics of antiphospholipid syndrome. Curr. Rheumatol. Rep. 21, 65 (2019).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1269_CR151","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.jtha.2025.03.029","volume":"23","author":"V Pengo","year":"2025","unstructured":"Pengo, V. & Pozzi, N. Lupus anticoagulant and antiprothrombin antibodies: embracing the future. J. Thromb. Haemost. 23, 2262\u20132269 (2025).","journal-title":"J. Thromb. Haemost."},{"key":"1269_CR152","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/humrep\/deab153","volume":"36","author":"E Grandone","year":"2021","unstructured":"Grandone, E. et al. Findings from a multicentre, observational study on reproductive outcomes in women with unexplained recurrent pregnancy loss: the OTTILIA registry. Hum. Reprod. 36, 2083\u20132090 (2021).","journal-title":"Hum. Reprod."},{"key":"1269_CR153","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1161\/CIRCULATIONAHA.113.007664","volume":"130","author":"G Piazza","year":"2014","unstructured":"Piazza, G. Thrombophilia testing, recurrent thrombosis, and women\u2019s health. Circulation 130, 283\u2013287 (2014).","journal-title":"Circulation"},{"key":"1269_CR154","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jtha.2024.10.022","volume":"23","author":"KMJ Devreese","year":"2025","unstructured":"Devreese, K. M. J. et al. An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC subcommittee on lupus anticoagulant\/antiphospholipid antibodies. J. Thromb. Haemost. 23, 731\u2013744 (2025).","journal-title":"J. Thromb. Haemost."},{"key":"1269_CR155","doi-asserted-by":"crossref","unstructured":"Wolgast, L. R. in Transfusion Medicine and Hemostasis 3rd edn (eds Shaz, B. H., Hillyer, C. D. & Reyes Gil, M.) 925\u2013931 (Elsevier, 2019).","DOI":"10.1016\/B978-0-12-813726-0.00158-6"},{"key":"1269_CR156","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1016\/j.jtha.2024.04.016","volume":"22","author":"A Vandevelde","year":"2024","unstructured":"Vandevelde, A. et al. Toward harmonized interpretation of anticardiolipin and anti-beta2-glycoprotein I antibody detection for diagnosis of antiphospholipid syndrome using defined level intervals and likelihood ratios: communication from the ISTH SSC subcommittee on lupus anticoagulant\/antiphospholipid antibodies. J. Thromb. Haemost. 22, 2345\u20132362 (2024).","journal-title":"J. Thromb. Haemost."},{"key":"1269_CR157","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1111\/jth.14846","volume":"18","author":"A Tripodi","year":"2020","unstructured":"Tripodi, A., Cohen, H. & Devreese, K. M. J. Lupus anticoagulant detection in anticoagulated patients. Guidance from the scientific and standardization committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. J. Thromb. Haemost. 18, 1569\u20131575 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"1269_CR158","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1212\/WNL.41.4.525","volume":"41","author":"DC Hess","year":"1991","unstructured":"Hess, D. C. et al. Anticardiolipin antibodies: a study of frequency in TIA and stroke. Neurology 41, 525\u2013528 (1991).","journal-title":"Neurology"},{"key":"1269_CR159","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000496","volume":"94","author":"X Qi","year":"2015","unstructured":"Qi, X. et al. Associations of antiphospholipid antibodies with splanchnic vein thrombosis: a systematic review with meta-analysis. Medicine 94, e496 (2015).","journal-title":"Medicine"},{"key":"1269_CR160","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5603\/jtm.97795","volume":"16","author":"J Musia\u0142","year":"2023","unstructured":"Musia\u0142, J. New classification criteria for antiphospholipid syndrome \u2014 2023. J. Transfus. Med. 16, 103\u2013109 (2023).","journal-title":"J. Transfus. Med."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-026-01269-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-026-01269-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-026-01269-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:02:49Z","timestamp":1789128169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-026-01269-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":160,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1269"],"URL":"https:\/\/doi.org\/10.1038\/s41569-026-01269-9","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"16 February 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.D.B. has received grant funding from Boston Scientific and has received consulting fees from Anthos, AstraZeneca, Bayer, Boston Scientific, Bristol Myers Squibb, Janssen, Novartis, Pfizer and Sanofi. M.L.O\u2019D. has received grant funding via Brigham and Women\u2019s Hospital, USA, from Amgen, AstraZeneca, Marea and Novartis, and consulting and\/or Data and Safety Monitoring Board fees from Amgen, AstraZeneca, Janssen, New Amsterdam, Novartis, Novo Nordisk and Verve. C.T.R. has received research grants through his institution (Brigham and Women\u2019s Hospital, USA) from Anthos, AstraZeneca, Daiichi Sankyo, Janssen and Novartis, has received honoraria for scientific advisory boards and consulting from Anthos, Bayer, Bristol Myers Squibb, Daiichi Sankyo and Janssen, and is a member of the TIMI Study Group, which has received institutional research grant support through Brigham and Women\u2019s Hospital, USA, from Abbott, Abiomed, Amgen, Anthos Therapeutics, ARCA Biopharma, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Ionis Pharmaceuticals, Janssen Research and Development, LLC, MedImmune, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, Saghmos Therapeutics, Siemens Healthcare Diagnostics, Softcell Medical, The Medicines Company, Verve Therapeutics, and Zora Biosciences. M.G. has received consulting fees from Genomadix and Werfen, is the primary investigator of the following active grant: Sapienza University of Rome (grant protocol no. RG1241910F5A1A50), and is an Associate Editor of the\n                      European Heart Journal\n                      . B.N.W. has received grant funding from Bristol Myers Squibb, Novo Nordisk and Oruka. R.D.L. has received research grants from Amgen, Bristol Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer and Sanofi, funding for educational activities or lectures from Daiichi Sankyo, Novo Nordisk and Pfizer, and funding for consulting from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Novo Nordisk and Pfizer. In the past 3 years, H.M.K. has received options for Element Science and Identifeye and payments from F-Prime for advisory roles, he was a cofounder of and has held equity in Hugo Health, is a cofounder of and holds equity in Refactor Health and ENSIGHT-AI, and is associated with research contracts through Yale University, USA, from Janssen, Kenvue, Novartis and Pfizer. M.S.V.E. receives a salary as an employee of the American Heart Association. G.P. has received research support paid to his institution (Brigham and Women\u2019s Hospital, USA) from Alexion, Amgen, Bayer, Boston Scientific Corporation, Bristol Myers Squibb\/Pfizer Alliance, Esperion, Janssen and Regeneron, and consulting fees from Boston Scientific Corporation, Bristol Myers Squibb\/Pfizer Alliance, Janssen, NAMSA, Penumbra and Thrombolex. B.\u00a0Bikdeli is a member of the Medical Advisory Board for the VasuLearn Network, serves on the Data Safety and Monitoring Board of the NAIL-IT trial funded by the National Heart, Lung, and Blood Institute and Translational Sciences, is a collaborating consultant with the International Consulting Associates and the FDA in a study to generate knowledge about utilization, predictors, retrieval and safety of IVC filters, and receives compensation as an Associate Editor for the\n                      New England Journal of Medicine\n                      Journal Watch Cardiology, as an Associate Editor for\n                      Thrombosis Research\n                      and as an Executive Associate Editor for the\n                      Journal of the American College of Cardiology\n                      , and is a Section Editor for\n                      Thrombosis and Haemostasis\n                      (no compensation). The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}